NO20062339L - Hepatitt C virus-inhibitoerer - Google Patents
Hepatitt C virus-inhibitoererInfo
- Publication number
- NO20062339L NO20062339L NO20062339A NO20062339A NO20062339L NO 20062339 L NO20062339 L NO 20062339L NO 20062339 A NO20062339 A NO 20062339A NO 20062339 A NO20062339 A NO 20062339A NO 20062339 L NO20062339 L NO 20062339L
- Authority
- NO
- Norway
- Prior art keywords
- hepatitis
- virus inhibitors
- compounds
- virus
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Hepatitt C virus-inhibitorer er beskrevet som har den generelle formel (I) hvor A, R2, R3, R', B og Y er beskrevet i beskrivelsen. Preparater omfattende forbindelsene og metoder for anvendelse av forbindelsene for å hemme HCV er også beskrevet.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52371703P | 2003-11-20 | 2003-11-20 | |
PCT/US2004/039331 WO2005051410A1 (en) | 2003-11-20 | 2004-11-19 | Hepatitis c virus inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062339L true NO20062339L (no) | 2006-08-10 |
Family
ID=34632819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062339A NO20062339L (no) | 2003-11-20 | 2006-05-23 | Hepatitt C virus-inhibitoerer |
Country Status (6)
Country | Link |
---|---|
US (1) | US7135462B2 (no) |
EP (1) | EP1684787B1 (no) |
JP (1) | JP4688815B2 (no) |
IS (1) | IS8476A (no) |
NO (1) | NO20062339L (no) |
WO (1) | WO2005051410A1 (no) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9712544B1 (pt) | 1996-10-18 | 2013-10-22 | Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos | |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US7176208B2 (en) * | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI389908B (zh) * | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
EP2305695A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
JP5015154B2 (ja) | 2005-08-12 | 2012-08-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ウイルスポリメラーゼインヒビター |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
BRPI0617274A2 (pt) | 2005-10-11 | 2011-07-19 | Intermune Inc | compostos e métodos para a inibição de replicação viral de hepatite c |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US20080187516A1 (en) * | 2006-06-06 | 2008-08-07 | Ying Sun | Acyclic oximyl hepatitis c protease inhibitors |
US7728148B2 (en) * | 2006-06-06 | 2010-06-01 | Enanta Pharmaceuticals, Inc. | Acyclic oximyl hepatitis C protease inhibitors |
RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
EP2049474B1 (en) | 2006-07-11 | 2015-11-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
WO2008008502A1 (en) * | 2006-07-13 | 2008-01-17 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication |
US20090035267A1 (en) * | 2007-07-31 | 2009-02-05 | Moore Joel D | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors |
US7635683B2 (en) * | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
US20080038225A1 (en) * | 2006-08-11 | 2008-02-14 | Ying Sun | Triazolyl acyclic hepatitis c serine protease inhibitors |
US7687459B2 (en) | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
AU2007284027A1 (en) | 2006-08-17 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2008070358A2 (en) * | 2006-11-16 | 2008-06-12 | Phenomix Corporation | N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2008074035A1 (en) | 2006-12-27 | 2008-06-19 | Abbott Laboratories | Hcv protease inhibitors and uses thereof |
EP2495249A1 (en) * | 2007-02-26 | 2012-09-05 | Achillion Pharmaceuticals, Inc. | Tertiary amine substituted peptides useful as inhibitors of HCV replication |
PL2144604T3 (pl) | 2007-02-28 | 2012-02-29 | Conatus Pharmaceuticals Inc | Sposoby leczenia przewlekłego zapalenia wątroby typu C z zastosowaniem RO 113-0830 |
US8377872B2 (en) * | 2007-04-26 | 2013-02-19 | Enanta Pharmaceuticals, Inc. | Cyclic P3 tripeptide hepatitis C serine protease inhibitors |
US20080267917A1 (en) * | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
EP2185524A1 (en) | 2007-05-10 | 2010-05-19 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
US20090047252A1 (en) * | 2007-06-29 | 2009-02-19 | Gilead Sciences, Inc. | Antiviral compounds |
EP2188274A4 (en) | 2007-08-03 | 2011-05-25 | Boehringer Ingelheim Int | VIRAL POLYMERASE HEMMER |
JP2010540549A (ja) * | 2007-09-24 | 2010-12-24 | アキリオン ファーマシューティカルズ,インコーポレーテッド | ウイルス複製阻害剤としての尿素含有ペプチド |
WO2009070689A1 (en) * | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease |
US8263549B2 (en) * | 2007-11-29 | 2012-09-11 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors |
US8361958B2 (en) * | 2007-12-05 | 2013-01-29 | Enanta Pharmaceuticals, Inc. | Oximyl HCV serine protease inhibitors |
JP5529036B2 (ja) | 2007-12-05 | 2014-06-25 | エナンタ ファーマシューティカルズ インコーポレイテッド | フッ素化トリペプチドhcvセリンプロテアーゼ阻害剤 |
CN101903351B (zh) | 2007-12-19 | 2014-09-10 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
JP5755449B2 (ja) * | 2007-12-21 | 2015-07-29 | セルジーン アビロミクス リサーチ, インコーポレイテッド | Hcvプロテアーゼ阻害剤およびその使用 |
US8309685B2 (en) * | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
TWI487522B (zh) * | 2007-12-21 | 2015-06-11 | 賽基艾維洛米斯研究股份有限公司 | Hcv蛋白酶抑制劑及其用途(一) |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
WO2009094443A1 (en) * | 2008-01-24 | 2009-07-30 | Enanta Pharmaceuticals, Inc. | Difluorinated tripeptides as hcv serine protease inhibitors |
JP2011510926A (ja) * | 2008-01-24 | 2011-04-07 | エナンタ ファーマシューティカルズ インコーポレイテッド | ヘテロアリール含有トリペプチドhcvセリンプロテアーゼ阻害剤 |
ES2437147T3 (es) | 2008-02-04 | 2014-01-09 | Idenix Pharmaceuticals, Inc. | Inhibidores de serina proteasa macrocíclicos |
JP5608563B2 (ja) * | 2008-02-25 | 2014-10-15 | メルク・シャープ・アンド・ドーム・コーポレーション | 治療用化合物 |
CA2719008A1 (en) * | 2008-03-20 | 2009-09-24 | Enanta Pharmaceuticals, Inc. | Fluorinated macrocyclic compounds as hepatitis c virus inhibitors |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8211891B2 (en) * | 2008-04-30 | 2012-07-03 | Enanta Pharmaceuticals, Inc. | Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors |
WO2009148923A1 (en) | 2008-05-29 | 2009-12-10 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
PT2364309E (pt) * | 2008-12-10 | 2015-01-14 | Achillion Pharmaceuticals Inc | Novos péptidos 4-amino-4-oxobutanoil como inibidores de replicação viral |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2385838A1 (en) | 2009-01-07 | 2011-11-16 | Scynexis, Inc. | Cyclosporine derivative for use in the treatment of hcv and hiv infection |
TWI438200B (zh) | 2009-02-17 | 2014-05-21 | 必治妥美雅史谷比公司 | C型肝炎病毒抑制劑 |
US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
US8936781B2 (en) | 2009-05-13 | 2015-01-20 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis C virus inhibitors |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
WO2011049908A2 (en) * | 2009-10-19 | 2011-04-28 | Enanta Pharmaceuticals, Inc. | Bismacrokyclic compounds as hepatitis c virus inhibitors |
US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
HUE028384T2 (en) | 2010-09-21 | 2016-12-28 | Enanta Pharm Inc | HCV serine protease inhibitors derived from macrocyclic proline |
CN103249730A (zh) | 2010-09-24 | 2013-08-14 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
EP2658858A4 (en) | 2010-12-30 | 2014-06-25 | Enanta Pharm Inc | MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE |
WO2012092409A2 (en) | 2010-12-30 | 2012-07-05 | Enanta Phararmaceuticals, Inc | Macrocyclic hepatitis c serine protease inhibitors |
WO2012109398A1 (en) | 2011-02-10 | 2012-08-16 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2780026B1 (en) | 2011-11-15 | 2019-10-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
PT2909205T (pt) | 2012-10-19 | 2017-02-06 | Bristol Myers Squibb Co | Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2- a)(1,4)diazaciclopentadecinilo substituídos com 9-metilo como inibidores da protease não estrutural 3 (ns3) para o tratamento de infeções por vírus da hepatite c |
US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
CA2905433A1 (en) | 2013-03-14 | 2014-09-25 | Achillion Pharmaceuticals, Inc. | Novel processes for producing sovaprevir |
MX2015013020A (es) | 2013-03-15 | 2016-06-10 | Achillion Pharmaceuticals Inc | Polimorfos de sovaprevir y metodos de fabricacion de los mismos. |
WO2014145600A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof |
CA2902569A1 (en) | 2013-03-15 | 2014-09-18 | Gilead Sciences, Inc. | Inhibitors of hepatitis c virus |
US9006423B2 (en) | 2013-03-15 | 2015-04-14 | Achillion Pharmaceuticals Inc. | Process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
CN103396351B (zh) * | 2013-08-09 | 2015-10-21 | 山东大学 | 吡咯烷类Bcl-2蛋白小分子抑制剂化合物及其制备、药物组合物与制药用途 |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
RU2702109C1 (ru) | 2014-02-05 | 2019-10-04 | Новира Терапьютикс, Инк. | Комбинированная терапия для лечения инфекций вгв |
US20220235013A1 (en) | 2017-03-21 | 2022-07-28 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
US20220274979A1 (en) | 2018-04-18 | 2022-09-01 | Bayer Pharma Aktiengesellschaft | 2-methyl-aza-quinazolines |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04271148A (ja) * | 1991-02-27 | 1992-09-28 | Hitachi Ltd | ソケット |
JP2624007B2 (ja) * | 1991-04-11 | 1997-06-25 | 松下電器産業株式会社 | 電話機等の操作パネル |
US5610054A (en) | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
GB9517022D0 (en) | 1995-08-19 | 1995-10-25 | Glaxo Group Ltd | Medicaments |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
CA2254122A1 (en) | 1996-05-10 | 1997-11-20 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
BR9712544B1 (pt) | 1996-10-18 | 2013-10-22 | Inibidores de proteases de serina, composição farmacêutica compreendendo os mesmos e seus usos | |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
AU7127298A (en) | 1997-04-14 | 1998-11-11 | Emory University | Serine protease inhibitors |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
EP1012180B1 (en) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptide analogues |
AU757783B2 (en) | 1997-08-11 | 2003-03-06 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
WO1999050230A1 (en) | 1998-03-31 | 1999-10-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
WO2000006529A1 (en) | 1998-07-27 | 2000-02-10 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti S.P.A. | Diketoacid-derivatives as inhibitors of polymerases |
AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
KR20010099623A (ko) | 1998-08-21 | 2001-11-09 | 비로파마 인코포레이티드 | 바이러스 감염 및 관련 질병을 치료 또는 예방하는화합물, 조성물 및 방법 |
BR9913406A (pt) | 1998-09-04 | 2002-01-29 | Viropharma Inc | Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção |
EP1115286A4 (en) | 1998-09-25 | 2003-07-23 | Viropharma Inc | METHOD FOR TREATING AND PREVENTING VIRAL INFECTIONS AND DISEASES RELATED TO THEM |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
ID30204A (id) | 1999-12-27 | 2001-11-15 | Japan Tobacco Inc | Senyawa-senyawa cincin terfusi dan penggunaannya sebagai obat |
AU2001261377A1 (en) | 2000-05-10 | 2001-11-20 | Smith Kline Beecham Corporation | Novel anti-infectives |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
BR0115447A (pt) * | 2000-11-20 | 2005-10-18 | Bristol Myers Squibb Co | Inibidores de tripeptìdeo de hepatite c |
CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
CA2370396A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
ATE503764T1 (de) * | 2002-05-20 | 2011-04-15 | Bristol Myers Squibb Co | Inhibitoren des hepatitis-c-virus |
AU2003301959A1 (en) * | 2002-05-20 | 2004-06-03 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
ATE481106T1 (de) | 2002-05-20 | 2010-10-15 | Bristol Myers Squibb Co | Heterocyclische sulfonamid-hepatitis-c-virus- hemmer |
CA2516016C (en) * | 2003-03-05 | 2012-05-29 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibiting compounds |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
-
2004
- 2004-11-18 US US10/992,548 patent/US7135462B2/en active Active
- 2004-11-19 WO PCT/US2004/039331 patent/WO2005051410A1/en not_active Application Discontinuation
- 2004-11-19 EP EP04811956.4A patent/EP1684787B1/en active Active
- 2004-11-19 JP JP2006541656A patent/JP4688815B2/ja not_active Expired - Fee Related
-
2006
- 2006-05-18 IS IS8476A patent/IS8476A/is unknown
- 2006-05-23 NO NO20062339A patent/NO20062339L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1684787B1 (en) | 2014-04-16 |
EP1684787A1 (en) | 2006-08-02 |
US7135462B2 (en) | 2006-11-14 |
WO2005051410B1 (en) | 2005-09-09 |
EP1684787A4 (en) | 2009-08-05 |
WO2005051410A9 (en) | 2005-07-28 |
US20050267040A1 (en) | 2005-12-01 |
IS8476A (is) | 2006-05-18 |
JP2007535491A (ja) | 2007-12-06 |
WO2005051410A1 (en) | 2005-06-09 |
JP4688815B2 (ja) | 2011-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062339L (no) | Hepatitt C virus-inhibitoerer | |
NO20062267L (no) | Hepatitt C virus inhibitorer | |
NO20044807L (no) | Heratitt C virus inhibitorer | |
NO20062185L (no) | Hepatitt C virus-inhibitorer | |
NO20091704L (no) | Inhibitorer av hepatitt C virus | |
NO20091707L (no) | Inhibitorer av hepatitt C virus | |
NO20091706L (no) | Inhibitorer av hepatitt C virus | |
NO20091591L (no) | Hepatitt C virusinhibitorer | |
WO2002048157A3 (en) | Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors | |
MXPA06012595A (es) | Analogos de amino-tetrazoles y metodos de uso. | |
DK1654261T3 (da) | Hepatitis C-inhibitorforbindelser | |
NO20061822L (no) | Makrosykliske inhibitorer av hepatitt C-virus-NS3-serinprotease | |
NO20070557L (no) | Ftalazinderivater som PARP-inhibitorer | |
WO2004014852A3 (en) | Iminothiazolidinones as inhibitors of hcv replication | |
ATE338461T1 (de) | Pyrazolpyrimidinfungizide | |
ATE486889T1 (de) | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c | |
IL198741A0 (en) | Hepatitis c virus inhibitor compounds, compositions containing the same and uses thereof | |
DE602005014804D1 (de) | Substituierte 5-carboxyamidpyrazoles und ä1,2,4ütriazole als viruzide | |
TW200615275A (en) | Hepatitis C inhibitor dipeptide analogs | |
WO2004062613A3 (en) | Hiv integrase inhibitors | |
DE602004020730D1 (de) | Pharmazeutisches verfahren und damit hergestellte verbindungen | |
TNSN07439A1 (en) | Derivatives of,4,5 - diarylpyrrole, preparation method thereof and use of same in therapeutics | |
ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |